Twin Lakes Capital Management LLC Acquires Shares of 557 Solventum Co. (NYSE:SOLV)

Twin Lakes Capital Management LLC acquired a new position in Solventum Co. (NYSE:SOLVFree Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 557 shares of the company’s stock, valued at approximately $29,000.

Other hedge funds have also added to or reduced their stakes in the company. Fifth Lane Capital LP bought a new stake in shares of Solventum during the first quarter valued at approximately $826,000. Boit C F David purchased a new stake in Solventum during the 1st quarter valued at about $152,000. Mitsubishi UFJ Trust & Banking Corp purchased a new position in Solventum in the first quarter worth about $5,747,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in shares of Solventum in the first quarter worth approximately $209,000. Finally, LRI Investments LLC purchased a new stake in shares of Solventum during the first quarter valued at approximately $43,000.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Wells Fargo & Company decreased their price objective on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a report on Friday, August 9th. Argus initiated coverage on shares of Solventum in a report on Monday, June 24th. They set a “hold” rating on the stock. The Goldman Sachs Group increased their price objective on shares of Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a research report on Monday, August 12th. Wolfe Research assumed coverage on shares of Solventum in a research note on Thursday. They set a “peer perform” rating for the company. Finally, BTIG Research started coverage on Solventum in a research note on Thursday, September 5th. They issued a “neutral” rating on the stock. One equities research analyst has rated the stock with a sell rating and seven have given a hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $58.25.

View Our Latest Report on Solventum

Solventum Price Performance

NYSE:SOLV opened at $67.57 on Monday. The firm’s 50-day simple moving average is $62.70. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $96.05. The company has a current ratio of 1.31, a quick ratio of 0.96 and a debt-to-equity ratio of 2.90.

Solventum (NYSE:SOLVGet Free Report) last released its earnings results on Thursday, August 8th. The company reported $1.56 EPS for the quarter, topping the consensus estimate of $1.46 by $0.10. The company had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.05 billion. Solventum’s revenue was up .2% compared to the same quarter last year. As a group, analysts expect that Solventum Co. will post 6.38 EPS for the current fiscal year.

Solventum Company Profile

(Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Recommended Stories

Institutional Ownership by Quarter for Solventum (NYSE:SOLV)

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.